From the FDA Drug Label
Contraception Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO [see Drug Interactions (7.2), Use in Specific Populations (8. 3), and Clinical Pharmacology (12.3)]. MOUNJARO delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. (7.2) Females of Reproductive Potential: Advise females using oral contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation. (7.2,8.3,12.3)
Mounjaro Interference with COCP: Mounjaro may interfere with the efficacy of combined oral contraceptive pills (COCP) due to its effect on gastric emptying, which can impact the absorption of oral medications.
- Key Considerations:
- Patients using oral hormonal contraceptives should be advised to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with Mounjaro.
- The potential for reduced efficacy of COCP should be taken into account when prescribing Mounjaro to females of reproductive potential 1, 1.
From the Research
Mounjaro (tirzepatide) does not significantly interfere with combined oral contraceptive pills (COCPs). Patients can continue using their hormonal contraceptives while taking Mounjaro without needing additional contraceptive methods. Mounjaro, which is used for type 2 diabetes and weight management, works by activating GLP-1 and GIP receptors, which primarily affects blood glucose regulation and appetite. Unlike some medications that can reduce contraceptive effectiveness through enzyme induction or gastrointestinal effects, Mounjaro does not alter the metabolism of contraceptive hormones in the liver or significantly impact their absorption 2.
However, patients should be aware that Mounjaro may cause gastrointestinal side effects like nausea, vomiting, or diarrhea, particularly when starting treatment. In rare cases of severe vomiting or diarrhea occurring within 3-4 hours of taking an oral contraceptive pill, the contraceptive effectiveness might be temporarily reduced, and backup contraception should be considered for that cycle. As with any medication combination, patients should inform all their healthcare providers about all medications they are taking. The most recent and highest quality study on Mounjaro, published in 2023, supports its use without significant interference with COCPs 3.
Key points to consider:
- Mounjaro's mechanism of action does not significantly impact COCP effectiveness
- Gastrointestinal side effects may temporarily reduce COCP effectiveness in rare cases
- Patients should inform all healthcare providers about their medications
- Backup contraception may be necessary in cases of severe gastrointestinal side effects
- The latest study on Mounjaro, published in 2023, confirms its safe use with COCPs 3.